Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253669 · ClinicalTrials.gov registry record
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
A clinical trial of Brain and Central Nervous System Tumors and Thromboembolism, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- 110
- Enrollment target
- 9
- Study locations
NCT00253669 is a study of Brain and Central Nervous System Tumors and Thromboembolism that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 110 participants, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (39% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT00253669, a study of Brain and Central Nervous System Tumors and Thromboembolism, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas. PURPOSE: This clinical trial is studying risk factors for developing blood clots in patients who are undergoing cancer treatment for newly diagnosed gliomas.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER physiologic testing
- PROCEDURE management of therapy complications
Study Locations (9)
Alabama
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham - Birmingham
Florida
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2005-04 |
| Est. Completion | 2009-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00253669
The ClinicalTrials.gov registry entry for NCT00253669 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (39% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00253669 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00253669 about?
NCT00253669 is a clinical study titled "Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas". RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas. PURPOSE: This clinical trial is studying risk factors for developing blood clots in patients who are undergoing ...
What is the current status of trial NCT00253669?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2005-04. Estimated completion is 2009-08.
What conditions does trial NCT00253669 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors, Thromboembolism.
What interventions are being tested in trial NCT00253669?
The interventions under investigation include: laboratory biomarker analysis (OTHER), physiologic testing (OTHER), management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00253669?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00253669 being conducted?
This trial has 9 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.